Colesevelam HCl

PreclinicalSmall molecule

Colesevelam HCl is one of 106 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

LAMCompleted

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Type 1 Diabetes MellitusPreclinical

Active, not recruiting

LAMPreclinical

Completed

Competition

Competitive Landscape

150 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

3 2

GZR18

GGan & Lee Pharmaceuticals.

Phase 3

5 3

HDM1002

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

3 4

Elecoglipron

AstraZeneca

Phase 3

5 5

Imeglimin

PPoxel SA

Phase 3

1 6

Dorzagliatin

HHua Medicine Limited

Phase 3

—7

TG103

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 3

2 8

NOVOLIN R

Novo Nordisk

Preclinical

1 9

Adenocard

Astellas

Preclinical

1 10

Cipro

Bayer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Completed·HHealthPartners Institute·Phase 2/3·NCT00993824·21 enrolled

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT00484419·169 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT00145574·194 enrolled

Tics1 trial

Effects of Colesevelam HCl On Bile Acid Kinetics

Completed·KKineMed··NCT00476710·36 enrolled

Hepatitis1 trial

Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

Completed·UUniversity of California, San Diego·Phase 2·NCT01066364·59 enrolled

Type 1 Diabetes Mellitus1 trial

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

Completed·UUniversity of Colorado, Denver·N/A·NCT00938405·45 enrolled

3 more indications

Type 2 Diabetes Mellitus1 trial

The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

Completed·KKineMed·N/A·NCT01092663·61 enrolled

LAM1 trial

Mechanisms of Glucose Lowering Effect of Colesevelam HCl

Completed·CCarine Beysen·N/A·NCT00596427·60 enrolled

Acceptability1 trial

Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale

Completed·LLouisville Metabolic and Atherosclerosis Research Center·Phase 4·NCT01122108·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Colesevelam HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Colesevelam HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Colesevelam HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Daiichi Sankyo

Colesevelam HCl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes2 trials

Efficacy and Safety1 trial

Tics1 trial

Hepatitis1 trial

Type 1 Diabetes Mellitus1 trial

Type 2 Diabetes Mellitus1 trial

LAM1 trial

Acceptability1 trial

References

Drug Info

Quick Facts

Related News